Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regencell Bioscience Holdings Limited - Ordinary Shares (NQ:RGC)

26.99 -2.18 (-7.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Regencell Bioscience Holdings Limited - Ordinary Shares

News headline image
Bragar Eagel & Squire, P.C. Continues Investigations into Regencell and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Continues Investigations into Regencell and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Continues Investigations into Regencell, Beyond Meat, Alvotech, and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Regencell, Beyond Meat, Alvotech, and Camping World and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial
From Regencell Bioscience Holdings Limited
Via Business Wire
News headline image
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period
From Regencell Bioscience Holdings Limited
Via Business Wire
News headline image
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO
From Regencell Bioscience Holdings Limited
Via Business Wire
News headline image
Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN Network
LOS ANGELES, CA / ACCESSWIRE / March 1, 2022 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with the team from Regencell Bioscience Holdings... 
From Stock News Now
Via AccessWire
News headline image
Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial
From Regencell Bioscience Holdings Limited
Via Business Wire
News headline image
Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors
From Regencell Bioscience Holdings Limited
Via Business Wire
News headline image
Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEO
From Regencell Bioscience Holdings Limited
Via Business Wire
News headline image
Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index
From Regencell Bioscience Holdings Limited
Via Business Wire
News headline image
Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment
From Regencell Bioscience Holdings Limited
Via Business Wire
News headline image
Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter’s Over-Allotment Option
From Regencell Bioscience Holdings Limited
Via Business Wire
News headline image
Regencell Bioscience Holdings Limited Releases CEO Letter to Shareholders
From Regencell Bioscience Holdings Limited
Via Business Wire
News headline image
Regencell Bioscience Holdings Limited Announces Closing of Initial Public Offering
From Regencell Bioscience Holdings Limited
Via Business Wire
News headline image
Regencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering
From Regencell Bioscience Holdings Limited
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.